Cogent Biosciences, Inc. (COGT): Price and Financial Metrics
GET POWR RATINGS... FREE!
COGT Stock Price Chart Interactive Chart >
COGT Price/Volume Stats
|Current price||$4.73||52-week high||$11.06|
|Prev. close||$4.56||52-week low||$3.79|
|Day high||$4.81||Avg. volume||259,025|
|50-day MA||$6.80||Dividend yield||N/A|
|200-day MA||$7.75||Market Cap||216.72M|
Cogent Biosciences, Inc. (COGT) Company Bio
Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a Âbolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Most Popular Stories View All
COGT Latest News Stream
|Loading, please wait...|
COGT Latest Social Stream
View Full COGT Social Stream
Latest COGT News From Around the Web
Below are the latest news stories about Cogent Biosciences Inc that investors may wish to consider to help them evaluate COGT as an investment opportunity.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Albireo Pharma (ALBO – Research Report) and Cogent Biosciences (COGT – Research Report) with bullish sentiments. Albireo Pharma (ALBO) Wedbush analyst Liana Moussatos reiterated a Buy rating on Albireo Pharma today and set a price target of $84.00. The company's shares closed last Wednesday at $24.31. According to TipRanks.
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided 2021 year-end updates and corporate guidance for 2022.
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President will participate in a fireside chat and one-on-one investor meetings during the Piper Sandler 33rd Annual Healthcare Conference, taking place virtually November 29 – December 2, 2021.
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced financial results for the third quarter ended September 30, 2021 and provided corporate updates.
COGT Price Returns